Market Overview

UPDATE: Allergan Confirms Receipt of Unsolicited Proposal from Valeant, Will Review Offer

Share:
Related AGN
JPMorgan: Monsanto Shares Could Hit $180 Over The Next 5 Years
Allergan Says FDA Accepts Its NDA Filing Of Oxymetazoline HCI Cream 1.0%
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q1 2016 Update (Seeking Alpha)
Related VRX
Report: Valeant Rejected A Takeover Offer Prior To Hiring Papa As CEO
The Market In 5 Minutes: Happy Memorial Day Weekend
Valeant Pharmaceuticals Is Breaking Out (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (“Valeant”) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company (the “Proposal”).

The Allergan Board of Directors, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the Company's stockholders. The Company's stockholders do not need to take any action at this time.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins is serving as legal counsel to the Company.

Posted-In: News M&A Press Releases

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!